Entering text into the input field will update the search result below

Magenta Therapeutics on deck for IPO

  • Cambridge, MA-based Magenta Therapeutics (NASDAQ:MGTA) has filed a preliminary prospectus for a $100M IPO.
  • The clinical-stage biotech develops treatments that extend the curative power of bone marrow transplantation, specifically a stem cell biology discovery platform and portfolio of novel therapeutics that the company says enables much safer patient preparation and improved prospects for success. Lead candidate is Phase 2-stage MGTA-456, a cell therapy derived from cord blood for the potential treatment of blood cancers and inherited metabolic diseases.
  • 2018 Financials (Q1)($M): Operating Expenses: 11.3 (+135.4%); Net Loss: (11.2) (-116.1%); Cash Burn: (9.6) (-138.3%).
  • HSCT-related tickers: BLCM, OMER, NVS, APOP

Recommended For You

About DNTH Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
DNTH--
Dianthus Therapeutics, Inc.